alpha-aminopyridine has been researched along with Substance Withdrawal Syndrome in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (23.08) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clepce, M; Kornhuber, J; Reich, K; Thuerauf, N; Wielopolski, J | 1 |
| Hennings, JM; Ising, M; Klengel, T; Knop, M; Rosenhagen, MC | 1 |
| Dong, L; Jiang, Q; Liu, H; Pang, G; Stackman, RW; Tao, X; Wu, X; Zhang, G; Zhang, YM | 1 |
| Bleich, S; Heberlein, A; Hillemacher, T; Kornhuber, J; Stoessel, C | 1 |
| Breese, GR; Knapp, DJ; Moy, SS; Overstreet, DH | 2 |
| Chevrette, J; Harrison, AA; Hoyer, D; Markou, A | 1 |
| Adrian, R; Koob, GF; Solbrig, MV; Wechsler, SL | 1 |
| Breese, GR; Knapp, DJ; Overstreet, DH | 1 |
| Bashore, TM; Evans, JR; Huss, P; Leier, CV; Pacht, K; Unverferth, DV | 1 |
| Agoston, S; Houwertjes, MC; Ket, JM; Maestrone, E; Uges, DR; van Hezik, EJ | 1 |
| Harrison, AA; Liem, YT; Markou, A | 1 |
| Aigner, M; Herrmann, WM; Kern, U | 1 |
2 trial(s) available for alpha-aminopyridine and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
Chronic oral amrinone therapy in congestive heart failure: a double-blind placebo-controlled withdrawal study.
Topics: Administration, Oral; Adult; Aged; Aminopyridines; Amrinone; Cardiotonic Agents; Clinical Trials as Topic; Double-Blind Method; Exercise Test; Female; Heart Failure; Humans; Male; Middle Aged; Platelet Count; Substance Withdrawal Syndrome | 1984 |
On the adverse reactions and efficacy of long-term treatment with flupirtine: preliminary results of an ongoing twelve-month study with 200 patients suffering from chronic pain states in arthrosis or arthritis.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Analgesics; Arthritis, Rheumatoid; Chronic Disease; Clinical Trials as Topic; Drug Tolerance; Female; Humans; Long-Term Care; Male; Middle Aged; Palliative Care; Substance Withdrawal Syndrome; Substance-Related Disorders | 1987 |
11 other study(ies) available for alpha-aminopyridine and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
Long-term use of flupirtine leads to withdrawal symptoms and is associated with dependency.
Topics: Adult; Aminopyridines; Analgesics; Butyrophenones; Female; Humans; Substance Withdrawal Syndrome; Substance-Related Disorders | 2013 |
Hypothalamic-pituitary-adrenocortical axis activity as a potential predictor for withdrawal symptoms in addiction to flupirtine, a nonopiate analgesic.
Topics: Aminopyridines; Analgesics; Humans; Hypothalamo-Hypophyseal System; Male; Middle Aged; Pituitary-Adrenal System; Predictive Value of Tests; Substance Withdrawal Syndrome | 2014 |
Activation of serotonin 5-HT(2C) receptor suppresses behavioral sensitization and naloxone-precipitated withdrawal symptoms in morphine-dependent mice.
Topics: Aminopyridines; Analgesics, Opioid; Animals; Benzazepines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Indoles; Locomotion; Male; Mice; Mice, Inbred Strains; Morphine; Morphine Dependence; Naloxone; Narcotic Antagonists; Reaction Time; Receptor, Serotonin, 5-HT2C; Serotonin Antagonists; Substance Withdrawal Syndrome; Time Factors | 2016 |
Positive reinforcing effects of flupirtine--two case reports.
Topics: Adult; Aminopyridines; Analgesics; Humans; Low Back Pain; Male; Middle Aged; Pleasure; Substance Withdrawal Syndrome | 2010 |
A 5-HT1A agonist and a 5-HT2c antagonist reduce social interaction deficit induced by multiple ethanol withdrawals in rats.
Topics: Aminopyridines; Animals; Anxiety; Buspirone; Dose-Response Relationship, Drug; Ethanol; Ethylamines; Indoles; Piperazines; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Ritanserin; Serotonin Antagonists; Serotonin Receptor Agonists; Social Behavior; Substance Withdrawal Syndrome | 2003 |
SB242084, flumazenil, and CRA1000 block ethanol withdrawal-induced anxiety in rats.
Topics: Alcohol Drinking; Aminopyridines; Animals; Anxiety; Ethanol; Flumazenil; Indoles; Male; Pyridines; Pyrimidines; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome | 2004 |
Paroxetine combined with a 5-HT(1A) receptor antagonist reversed reward deficits observed during amphetamine withdrawal in rats.
Topics: Affective Symptoms; Aminopyridines; Amphetamine; Animals; Brain; Drug Synergism; Hypothalamus, Posterior; Male; Motivation; Norepinephrine; Paroxetine; Piperazines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reward; Selective Serotonin Reuptake Inhibitors; Self Stimulation; Serotonin 5-HT1 Receptor Antagonists; Substance Withdrawal Syndrome | 2005 |
Activators of potassium M currents have anticonvulsant actions in two rat models of encephalitis.
Topics: Aminopyridines; Analgesics; Animals; Anticonvulsants; Borna Disease; Encephalitis, Viral; Herpes Simplex; Herpesvirus 1, Human; Male; Naloxone; Naltrexone; Narcotic Antagonists; Potassium; Rats; Rats, Inbred Lew; Receptors, Opioid, delta; Seizures; Substance Withdrawal Syndrome | 2007 |
Drug challenges reveal differences in mediation of stress facilitation of voluntary alcohol drinking and withdrawal-induced anxiety in alcohol-preferring P rats.
Topics: Alcohol Drinking; Aminopyridines; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Benzodiazepines; Buspirone; Dopamine Antagonists; Ethanol; Flumazenil; GABA Modulators; Haloperidol; Indoles; Naloxone; Narcotic Antagonists; Olanzapine; Rats; Rats, Inbred Strains; Restraint, Physical; Serotonin Receptor Agonists; Stress, Physiological; Substance Withdrawal Syndrome | 2007 |
Effective treatment of verapamil intoxication with 4-aminopyridine in the cat.
Topics: 4-Aminopyridine; Aminopyridines; Animals; Antidotes; Blood Pressure; Cats; Heart Rate; Humans; Substance Withdrawal Syndrome; Verapamil | 1984 |
Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats.
Topics: Aminopyridines; Amphetamine; Amphetamine-Related Disorders; Animals; Body Weight; Brain; Depression; Disease Models, Animal; Drug Combinations; Electric Stimulation; Fluoxetine; Male; Mecamylamine; Neurons; Nicotine; Nicotinic Antagonists; Piperazines; Rats; Rats, Wistar; Reaction Time; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Reward; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Substance Withdrawal Syndrome; Synaptic Transmission; Tobacco Use Disorder | 2001 |